It started in 2011 with just a handful of drugs. CVS Caremark chucked 34 meds off its formulary, partly in a snit over copay coupons, partly just to see what would happen. Now, CVS' excluded list comprises almost 100 drugs and related products.
In 2011, CVS Caremark chucked 34 meds off its formulary, partly in a snit over copay coupons, partly just to see what would happen. It was a pilot program, the pharmacy benefits manager said. Now, CVS' excluded list comprises almost 100 drugs and related products.
GlaxoSmithKline giant Advair may be reeling, but it hasn't kicked the bucket yet. And now, it's getting a payer boost that will breathe a little life into falling sales. With dismal second-quarter results depressing investors, the news couldn't have come at a better time.
Express Scripts has struck again. The pharmacy benefits manager is barring another 25 drugs, including some aging heavyweights like Amgen's anemia drugs Aranesp and Epogen, and newer meds such as the controversial painkiller Zohydro, made by Zogenix.
When do rising drug prices not equal rising sales? When payers step in to control costs--and that's exactly what they've been doing.
The FDA is getting an earful from another group intent on saving money on biotech drugs. A coalition of pharmacies, health insurers, unions and pension plans asked the agency to allow biosimilar drugs to carry the same generic names as the drugs they copy. Easy to substitute the biosim for the brand, easier to cut biotech drug spending.
In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes from the second pharmacy benefits management report to be released in three days, this one from CVS Caremark following Express Scripts' missive on Tuesday.
Express Scripts released more stunning numbers on what could happen with spending on drugs to treat hepatitis C as it builds a case against the price Gilead Sciences has put on a drug that can cure the disease.
Which drugs cost U.S. health plans the most? Take a look at this year's iteration of Express Scripts' annual Drug Trend Report, and you'll find commentary on drug prices, the pharma industry, and American society. Not to mention a hint at which brands are best at getting themselves noticed.
Express Scripts and Gilead Sciences are playing a high-priced game of chicken. At stake is the fate of Sovaldi (sofosbuvir), Gilead's high-priced hepatitis C pill, and the future of hep C treatment in the U.S. Not to mention the future of Sovaldi rivals from AbbVie, Bristol-Myers Squibb, and more.